Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
- Sarraju, Ashish
- Li, JingWei
- Cannon, Christopher P.
- Chang, Tara
- Agarwal, Rajiv
- Bakris, George
- Charytan, David M.
- de Zeeuw, Dick
- Greene, Tom
- Heerspink, Hiddo J. L.
- Levin, Adeera
- Neal, Bruce
- Pollock, Carol
- Wheeler, David C.
- Yavin, Yshai
- Zhang, Hong
- Zinman, Bernard
- Perkovic, Vlado
- Jardine, Meg
- Mahaffey, Kenneth W.
DOIAbstract
We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P .150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure
Add to ORKG